The Board resolution dated July 24, 2021, the BOD of Imexpharm Corporation approved the following issues:

1)      Approving the business result in Quarter 2/2021:

-          Total revenue & other: 322.6 billion dongs

-          Net revenue: 317.4 billion dongs

-          Net profit from business activities: 60.0 billion dongs

-          Profit before tax: 61.8 billion dongs

-          Profit after tax: 49.3 billion dongs.

2)      Approving the progress report on the project of Binh Duong High Technology Plant until June 30, 2021.

3)      Approving the business plan in Quarter 3/2021.

4)      Approving the handle of bad debts with total amount of VND1,441,655,133.